Future-Proofing Human Capital: Does Biopharma Have The Right Stuff?
Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.
You may also be interested in...
2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
A Q&A on biopharma workforce recruitment, training and C-suite oversight with Halozyme's Ken Schultz, MD. A supplement to our feature on the In Vivo/EBD Academy survey, "Future-Proofing Human Capital in the Global Life Sciences: Does Biopharma Have the Right Stuff?
An interview with Odgers Berndtson's John Hawkins about the credentials needed for the next-gen biopharma C-suite. A supplement to our feature on the In Vivo/EBD Academy survey, “Future-Proofing Human Capital: Does Biopharma Have the Right Stuff?”